BioSpace News Archive

Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial.

Less than a year after taking over the reins, Biotechnology Innovation Organization Chief Executive Officer Michelle McMurry-Heath is reorganizing the organization’s leadership structure.

Expert in Value-Based Contracting and Network Management Will Deepen Relationships With Payers, Providers, and Academic Centers

eMed™, a digital health company democratizing healthcare through digital point-of-care solutions, today announced a partnership with the State of Ohio to distribute and administer at least 2 million virtually-guided, BinaxNOW™ at-home COVID-19 rapid tests, which deliver results within minutes.

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has committed $1.5 million to Penn State University to create the Sartorius Cell Culture Facility. It is slated to open in the first quarter of 2021 on the University Park campus.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has entered into securities purchase agreements with certain institutional and accredited invest

Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of an aggregate 2,500,000 shares of its common stock and warrants to purchase up to an aggregate of 2,500,000 shares of its common stock. Each share and corresponding warrant is

The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiret

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s fourth quarter and full year 2020 financial results and will provide a business update.